Last verified: April 4, 2026

If you have Medicare and you are trying to get a GLP-1 for weight loss, the short version is this: access may get easier in 2026, but it does not start for most Medicare patients in May. As of April 4, 2026, CMS says the first new Medicare access path starts July 1, 2026 through a temporary program called the Medicare GLP-1 Bridge. That bridge currently lists Wegovy and Zepbound, uses prior authorization, and sets a $50 monthly copay for people who qualify. [2]

The part that starts in May 2026 is mainly about state Medicaid participation, not broad Medicare access. The bigger, longer-term Medicare change is expected to arrive on January 1, 2027, when the separate BALANCE Model begins for Medicare Part D. [1] [2] [3]

Here is the timeline in plain English:

  • May 2026: state Medicaid agencies can start joining the BALANCE Model
  • July 1, 2026: the temporary Medicare GLP-1 Bridge begins
  • January 1, 2027: BALANCE is expected to begin for Medicare Part D [1] [2] [3]

What that means for you: if you are on Medicare and meet the bridge rules, you may have a new way to access Wegovy or Zepbound starting this summer. If you are hoping for automatic coverage, broader access to drugs like Ozempic or Mounjaro, or a permanent Part D benefit change, that is not what CMS has announced for 2026. [2] [3] [4]

If you want the broader medication background first, start with our GLP-1 guide. If you are comparing access routes, keep our insurance guide, telehealth comparison, brand vs. compounded guide, and semaglutide guide open too.

What the CMS BALANCE Model Actually Is

BALANCE stands for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth. CMS describes it as a voluntary model designed to increase access to select GLP-1 drugs and healthy lifestyle interventions for people with Medicare and Medicaid. Under the model, CMS negotiates pricing and coverage terms with manufacturers on behalf of state Medicaid agencies and Medicare Part D sponsors. [1] [3]

Two details matter right away:

  • participation is voluntary for manufacturers, state Medicaid agencies, and Part D plans
  • BALANCE is not just drug coverage; CMS says beneficiaries receiving GLP-1s for weight management will also get access to a manufacturer-provided lifestyle support program at no cost [3]

So if you are asking, “Will all Medicare beneficiaries get this automatically?” the answer is no. CMS says coverage under BALANCE will depend on which manufacturers participate, which states or Part D sponsors participate, and whether the patient meets negotiated qualification rules. [3] [5]

The Date That Matters for Medicare in 2026

For Medicare, the first operational date is July 1, 2026, not May 2026.

CMS says the Medicare GLP-1 Bridge will run from July 1, 2026 through December 31, 2026. It is a separate short-term demonstration designed to give eligible Medicare Part D beneficiaries early access before the BALANCE Model starts in Part D on January 1, 2027. [1] [2]

The bridge also works differently from standard Part D:

  • it operates outside the normal Part D coverage and payment flow
  • CMS uses a single central processor for prior authorization, claims adjudication, and pharmacy payment
  • eligible beneficiaries pay a flat $50 monthly copay
  • the bridge is nationwide and does not require Part D plans to opt in for the temporary 2026 access path [2]

That is the cleanest way to understand the rollout:

  1. BALANCE changes the long-term policy structure.
  2. The bridge is the short-term Medicare access path for 2026.
  3. They are connected, but they are not the same program. [2] [3]

Which GLP-1 Drugs Are Covered

This is another place where headlines get sloppy.

For the 2026 Medicare GLP-1 Bridge

CMS currently says the bridge covers Wegovy and Zepbound when they are used to reduce excess body weight and maintain weight reduction. That is the current list on the CMS bridge page. [2]

That means:

  • Wegovy: yes, listed by CMS for the bridge
  • Zepbound: yes, listed by CMS for the bridge
  • Ozempic: no, not listed for bridge obesity coverage
  • Mounjaro: no, not listed for bridge obesity coverage
  • Rybelsus: no, not listed for bridge obesity coverage today [2]

For BALANCE in 2027

CMS says the BALANCE Model drug set is broader. The BALANCE page lists:

  • Mounjaro
  • Ozempic
  • Rybelsus
  • Wegovy
  • Zepbound KwikPen
  • the tablet formulation of orforglipron if FDA-approved by the relevant deadline [3]

That is an important distinction. A drug can be eligible for BALANCE in 2027 without being available through the narrower Medicare bridge in 2026.

Who Is Eligible

The bridge criteria are more restrictive than many readers expect. CMS says a provider must submit a prior authorization request showing that the beneficiary is using the drug together with ongoing lifestyle modification and that the patient met one of several BMI-based pathways at the time GLP-1 therapy started. [2]

BMI means body mass index, a weight-for-height screening tool that insurers often use in obesity coverage policies.

Under the current CMS bridge FAQ, the main pathways are:

  • BMI 35 or higher at treatment initiation
  • BMI 30 or higher at treatment initiation plus at least one of:
    • heart failure with preserved ejection fraction
    • uncontrolled hypertension
    • chronic kidney disease stage 3a or above
  • BMI 27 or higher at treatment initiation plus at least one of:
    • prediabetes
    • previous myocardial infarction
    • previous stroke
    • symptomatic peripheral artery disease [2]

That is not the same as saying, “Anyone on Medicare with obesity can get Wegovy.” CMS is using narrower negotiated access criteria for the bridge. [2] [4]

For BALANCE itself, CMS lists a closely related but not identical framework. The BALANCE page says patients must have provider-confirmed type 2 diabetes, or noncirrhotic MASH with moderate to advanced liver fibrosis, or obstructive sleep apnea, or be on ongoing lifestyle modification and meet one of the BMI-based pathways. CMS also includes obstructive sleep apnea and MASH in the BMI 30-plus pathway on that page. [3]

The practical takeaway is simple: you cannot assume the standard FDA obesity label is enough on its own. CMS is layering model-specific access rules on top.

Standard Part D Coverage Is Already Different for Some People

This is where many patients get tripped up.

Some Medicare beneficiaries can already get certain GLP-1 drugs covered under the normal Part D benefit when the prescription is tied to a covered FDA-approved use that is not obesity alone.

Two examples matter:

  • The FDA approved Wegovy in March 2024 to reduce the risk of major adverse cardiovascular events in adults with obesity or overweight and established cardiovascular disease. [7] [12]
  • The FDA approved Zepbound in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. [8]

CMS says requests for those covered uses still go through the beneficiary’s regular Part D plan and normal utilization-management process, not the temporary bridge. [2]

So if you are asking “Does Medicare cover Wegovy?” the honest answer is:

  • sometimes already, for cardiovascular risk reduction under regular Part D rules
  • more broadly for bridge-eligible obesity treatment, starting July 1, 2026
  • potentially through participating BALANCE Part D plans, starting January 1, 2027 [2] [3] [7]

Step by Step: How to Get Covered

If you are a Medicare beneficiary trying to use the new 2026 pathway, this is the practical checklist.

Step 1: Confirm you have a qualifying Part D setup

CMS says bridge eligibility requires enrollment in a standalone PDP or a Medicare Advantage plan with Part D drug coverage. CMS also says some plan types are not eligible unless the beneficiary is separately enrolled in a standalone PDP. [2]

Step 2: Figure out which coverage route fits your situation

There are now two different Medicare pathways:

  • regular Part D for a drug’s already covered indication, such as Wegovy for cardiovascular risk reduction or Zepbound for obstructive sleep apnea
  • the Medicare GLP-1 Bridge for qualified obesity-treatment access starting July 1, 2026 [2] [7] [8]

That difference changes where the paperwork goes.

Step 3: Have your prescriber document the right facts

For the bridge, CMS says the prior authorization must attest to:

  • the drug being prescribed for reduction of excess body weight and maintenance of weight reduction
  • current and ongoing lifestyle modification
  • the beneficiary’s qualifying BMI and comorbidity criteria
  • the fact that the criteria were met at treatment initiation, not just today [2]

That last point is easy to miss. CMS gives an example of someone who started treatment with a BMI of 37 and later dropped to 34. The bridge can still use the original BMI if the provider documents that the beneficiary met the criterion when therapy started. [2]

Step 4: Send the request to the right place

For bridge-covered obesity use, CMS says the provider sends the prior authorization request to the central processor, not to the Part D plan. For standard Part D-covered uses, the request still goes through the beneficiary’s plan. [2]

Step 5: Fill the prescription at a participating pharmacy

CMS says pharmacies do not need to opt in separately to the bridge, and the central processor will handle claims and payment. The beneficiary pays the pharmacy $50, and the central processor reimburses the rest of the covered bridge amount. [2]

What You May Pay

For the temporary bridge, CMS is unusually clear: the beneficiary copay is $50 per monthly supply. CMS also says the participating manufacturers provide eligible bridge drugs at a net price of $245 per monthly supply, but that negotiated net price is not the patient’s out-of-pocket cost. [2]

What CMS does not fully answer yet is what 2027 will look like plan by plan under BALANCE. KFF notes that the model is supposed to lower costs through negotiated prices and standardized terms, but the real beneficiary experience will still depend on participation and implementation details that are not fully published yet. [4] [5]

So the honest summary is:

  • July to December 2026 bridge: we have a clear $50 beneficiary number
  • January 2027 BALANCE: cost sharing is still not final enough to promise a universal number today

Your Pre-Appointment Medicare Checklist

If you want to save yourself two weeks of back-and-forth, go into the doctor visit with the paperwork logic already in mind.

Bring or prepare:

  • your current Part D card or Medicare Advantage drug coverage information
  • your starting weight, current weight, and if possible the chart date showing when GLP-1 therapy started
  • your most recent BMI and any prior BMI in the chart near treatment initiation
  • a list of qualifying diagnoses that may matter under CMS criteria:
    • prediabetes
    • prior heart attack
    • prior stroke
    • peripheral artery disease
    • heart failure with preserved ejection fraction
    • uncontrolled hypertension
    • chronic kidney disease stage 3a or higher
    • obstructive sleep apnea if the request may be framed under standard Part D Zepbound use
  • a simple timeline of what you have already tried for weight management, including nutrition changes, physical activity work, and any prior anti-obesity medication [2] [3]

Then ask the prescriber these five questions directly:

  1. Are you sending this through my regular Part D plan, or through the Medicare GLP-1 Bridge central processor?
  2. Which indication are you using on the request: obesity treatment, cardiovascular risk reduction, or obstructive sleep apnea?
  3. What BMI and diagnosis are you documenting as the qualifying criteria?
  4. Are you using my BMI at treatment initiation if that is the number that meets CMS criteria?
  5. Who in your office tracks the prior authorization after it is submitted?

Those questions sound basic, but they expose the real failure points fast. Many denials are not about whether the drug works. They are about whether the request was routed through the right channel with the right diagnosis and enough documentation.

If you are using a telehealth provider, ask one more question before paying any membership fee: Do you handle Medicare Part D and bridge prior authorization workflows yourself, or are you only writing the prescription? A service that only sends the prescription is not the same thing as a service that can navigate a Medicare coverage process.

The practical move for July 2026 is to treat this like a documentation project, not just a prescription request.

What This Means for the GLP-1 Market

This policy change matters beyond Medicare.

First, it changes the price anchor. If Medicare beneficiaries can access Wegovy or Zepbound through a $50 bridge copay, that becomes a real reference point in every discussion about cash-pay obesity treatment. [1] [2]

Second, it puts more pressure on telehealth providers to explain whether they actually work with Medicare. Many direct-to-consumer GLP-1 platforms are built around cash pay, commercial insurance, or compounded prescribing models. If you are comparing providers, ask a blunt question: Do you submit or support Medicare Part D prior authorization workflows, including the new bridge rules? If not, their marketing copy is not very useful to you.

Third, it weakens the lazy version of the “brand versus compounded” debate. When legitimate brand products become more accessible through Medicare at a documented $50 bridge copay, the economic case for compounded alternatives can look very different for some beneficiaries. That does not eliminate compounded demand. It does mean the cheapest apparent option is not always the real cheapest option anymore. [2] [3]

The Clinical Context Still Matters

Policy access matters, but people still want to know whether the covered drugs work.

In the STEP 1 trial, semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo. [10]

In SURMOUNT-1, tirzepatide 15 mg produced 20.9% mean body-weight loss at 72 weeks versus 3.1% with placebo. [11]

And in SELECT, semaglutide 2.4 mg reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease, which is why Wegovy’s Medicare story is now different from a pure obesity-only request. [12]

Those are not small numbers. They help explain why CMS is willing to build a bridge instead of waiting quietly for 2027.

What We Still Do Not Know

This is the section most sites skip, which is usually where the useful truth is.

We still do not know:

  • which Part D plans will opt into BALANCE for 2027
  • how smooth the bridge-to-BALANCE transition will be for patients already using the temporary program
  • the exact 2027 beneficiary cost-sharing structure across participating plans
  • how quickly newly approved products like orforglipron / Foundayo move from BALANCE eligibility language into real-world Medicare access
  • whether every prescriber and pharmacy workflow will be ready quickly enough for a smooth July 1 launch [2] [3] [5] [9]

There is also a Medicaid uncertainty. CMS says states can begin joining BALANCE in May 2026, but Medicaid obesity-drug coverage is still optional and patchy. KFF’s Medicaid analysis shows that state coverage remains uneven even before the model is layered in. [3] [6]

Bottom Line

The clean version is this:

  • May 2026 is mainly a Medicaid BALANCE milestone
  • July 1, 2026 is the first real Medicare obesity-drug access date through the temporary bridge
  • January 1, 2027 is when BALANCE is expected to start for Medicare Part D [1] [2] [3]

If you want the most practical GLP-1 coverage updates without reading every CMS memo yourself, get on the newsletter. That is where we send the policy shifts, price changes, and screenshot-friendly comparison tables that actually change what patients can do next.